How do insurance companies view cannabis treatments for fibromyalgia?

PostedFebruary 17, 2026

UpdatedFebruary 17, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

When it comes to insurance coverage for medical cannabis, the situation remains complicated. Despite the increasing acceptance of cannabis for chronic pain, most UK insurance providers still consider it outside the scope of standard fibromyalgia care. This means many patients must pay out of pocket unless future changes occur in policy or legislation.

The lack of consistent insurance coverage leaves a gap in affordability and access two major hurdles in long-term fibromyalgia care.

Key perspectives from insurers and current policies

Here’s how insurers are currently addressing medical cannabis for fibromyalgia treatment:

Limited Policy Inclusion

Most insurers do not include cannabis in their coverage policies, citing regulatory status and lack of large-scale clinical approval.

Case-by-Case Exceptions

In rare cases, insurance coverage may be approved for specific cannabis-based medications, but this typically requires exceptional documentation and pre-authorisation.

Focus on Traditional Therapies

Insurance providers tend to favour established treatments, such as physiotherapy, antidepressants, and NHS-approved drugs for fibromyalgia care.

Legal Ambiguities

Due to complex legal frameworks, many insurers remain cautious. Without clearer national guidelines, many default to exclusion rather than support.

Patient Advocacy Impact

As more patients and clinicians push for policy reform, there is growing pressure on providers to reconsider coverage policies, but changes are gradual.

At present, insurance coverage for cannabis remains minimal. Still, growing demand and improved understanding of patient outcomes may shift the conversation in the future.

If you’re exploring cannabis treatment options for fibromyalgia, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and Fibromyalgia.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.